Biocon Biologics, Viatris launch interchangeable biosimilars in US
Biocon Ltd. said that its subsidiary — Biocon Biologics and Viatris have launched interchangeable biosimilars SEMGLEE (insulin glargine-yfgn) injection, a branded product, and Insulin Glargine (insulin glargine-yfgn) injection, an unbranded product in the US.
The two products help regulate high blood sugar in adult as well as pediatric patients having type 1 diabetes and adults suffering from type 2 diabetes.
According to Biocon, the biosimilar products are available in vial and prefilled pen presentations. They can be interchanged for the reference brand — LANTUS (insulin glargine), thereby enabling substitution at the pharmacy counter.
Co-developed by Biocon Biologics and Viatris, SEMGLEE (insulin glargine-yfgn) and Insulin Glargine (insulin glargine-yfgn) are presently available in the US market.
The presently marketed non-interchangeable SEMGLEE (insulin glargine) is expected to be phased out by the end of this year, said Biocon.